GlobeNewswire: Aceto Corporation Contains the last 10 of 232 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T23:01:09ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/04/30/1812471/0/en/ACETO-Completes-the-Sale-of-Its-Chemicals-Business-Assets.html?f=22&fvtc=4&fvtv=6436ACETO Completes the Sale of Its Chemicals Business Assets2019-04-30T12:00:00Z<![CDATA[PORT WASHINGTON, N.Y., April 30, 2019 (GLOBE NEWSWIRE) -- ACETO Corporation (OTC: ACETQ) announced today that it has completed the previously disclosed sale of its chemicals business assets to an affiliate of New Mountain Capital, a leading growth-oriented investment firm with over $20 billion in assets under management.]]>https://www.globenewswire.com/news-release/2019/04/22/1807270/0/en/ACETO-Completes-the-Sale-of-Rising-Pharmaceuticals.html?f=22&fvtc=4&fvtv=6436ACETO Completes the Sale of Rising Pharmaceuticals2019-04-22T12:00:00Z<![CDATA[PORT WASHINGTON, N.Y., April 22, 2019 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq: ACETQ), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has completed the previously disclosed sale of the assets of Rising Pharmaceuticals and Rising’s subsidiaries to Shore Suven Pharma, Inc.]]>https://www.globenewswire.com/news-release/2019/04/15/1804350/0/en/ACETO-to-Sell-its-Chemicals-Business-Assets-to-New-Mountain-Capital.html?f=22&fvtc=4&fvtv=6436ACETO to Sell its Chemicals Business Assets to New Mountain Capital2019-04-15T21:00:00Z<![CDATA[PORT WASHINGTON, N.Y., April 15, 2019 (GLOBE NEWSWIRE) -- ACETO Corporation (OTC: ACETQ), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has agreed to sell its chemicals business assets to an affiliate of New Mountain Capital (“NMC”), a leading growth-oriented investment firm with over $20 billion in assets under management.]]>https://www.globenewswire.com/news-release/2019/04/12/1803473/0/en/ACETO-Receives-Court-Approval-of-Stalking-Horse-Agreement-to-Sell-Rising-Pharmaceuticals-to-Shore-Suven-Pharma-Inc.html?f=22&fvtc=4&fvtv=6436ACETO Receives Court Approval of “Stalking Horse” Agreement to Sell Rising Pharmaceuticals to Shore Suven Pharma, Inc.2019-04-12T14:45:00Z<![CDATA[PORT WASHINGTON, N.Y., April 12, 2019 (GLOBE NEWSWIRE) -- ACETO Corporation (OTC: ACETQ), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has received approval from the U.S. Bankruptcy Court to sell the assets of Rising Pharmaceuticals and Rising’s subsidiaries to Shore Suven Pharma, Inc. for gross cash proceeds of $15 million, plus the assumption of operating liabilities and customer obligations related to the acquired business, on a cash-free and debt-free basis.]]>https://www.globenewswire.com/news-release/2019/03/08/1750353/0/en/ACETO-Enters-into-Stalking-Horse-Agreement-to-Sell-Rising-Pharmaceuticals.html?f=22&fvtc=4&fvtv=6436ACETO Enters into “Stalking Horse” Agreement to Sell Rising Pharmaceuticals2019-03-08T03:04:29Z<![CDATA[PORT WASHINGTON, N.Y., March 07, 2019 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq: ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has entered into a “stalking-horse” asset purchase agreement with Shore Suven Pharma, Inc. to sell the assets of Rising Pharmaceuticals and Rising’s subsidiaries for gross cash proceeds of $15 million, plus the assumption of operating liabilities and customer obligations related to the acquired business on a cash-free and debt-free basis.]]>https://www.globenewswire.com/news-release/2019/02/20/1738620/0/en/ACETO-Announces-Receipt-of-Nasdaq-Notice-Due-to-Delay-in-Filing-Form-10-Q-for-the-Fiscal-Quarter-Ended-December-31-2018.html?f=22&fvtc=4&fvtv=6436ACETO Announces Receipt of Nasdaq Notice Due to Delay in Filing Form 10-Q for the Fiscal Quarter Ended December 31, 20182019-02-20T17:40:00Z<![CDATA[PORT WASHINGTON, N.Y., Feb. 20, 2019 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq: ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it received a notification from the Nasdaq Stock Market (“Nasdaq”) on February 13, 2019 informing Aceto that since Aceto had not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2018 (the “Quarterly Report”), Aceto was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The Listing Rule requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission. The Nasdaq notification letter specifies that Aceto has 60 calendar days, or until April 14, 2019, to submit a plan to regain compliance with the Listing Rule. If Nasdaq accepts the plan from Aceto, Nasdaq can grant an exception of up to 180 calendar days from the Quarterly Report’s due date, or until August 12, 2019, to regain compliance. Aceto filed the Quarterly Report prior to the opening of trading on February 20, 2019. The Quarterly Report, among other things, describes that on February 19, 2019, the Company and certain of its U.S. subsidiaries each filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code.]]>https://www.globenewswire.com/news-release/2019/02/20/1738026/0/en/ACETO-Announces-Proposed-Sale-of-its-Chemicals-Business-Assets-to-New-Mountain-Capital-for-338-million.html?f=22&fvtc=4&fvtv=6436ACETO Announces Proposed Sale of its Chemicals Business Assets to New Mountain Capital for $338 million2019-02-20T02:39:06Z<![CDATA[ACETO and its U.S. Subsidiaries File Voluntary Chapter 11 Petitions to Facilitate SaleSecures Commitment for Debtor-in-Possession Financing to Support Normal Course OperationsACETO Pursuing Court-Supervised Sale of Rising Pharmaceuticals]]>https://www.globenewswire.com/news-release/2018/11/08/1648608/0/en/ACETO-Reports-Fiscal-2019-First-Quarter-Results.html?f=22&fvtc=4&fvtv=6436ACETO Reports Fiscal 2019 First Quarter Results2018-11-08T21:30:00Z<![CDATA[PORT WASHINGTON, N.Y., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today financial results for the fiscal 2019 first quarter ended September 30, 2018.]]>https://www.globenewswire.com/news-release/2018/11/05/1645033/0/en/ACETO-Corporation-Adopts-Rights-Plan-Designed-to-Preserve-Valuable-Net-Operating-Loss-Carryforwards-and-Other-Tax-Benefits.html?f=22&fvtc=4&fvtv=6436ACETO Corporation Adopts Rights Plan Designed to Preserve Valuable Net Operating Loss Carryforwards and Other Tax Benefits2018-11-05T13:00:00Z<![CDATA[PORT WASHINGTON, N.Y., Nov. 05, 2018 (GLOBE NEWSWIRE) -- ACETO Corporation (NASDAQ:ACET) today announced that its Board of Directors has adopted a tax asset protection rights plan (the “Rights Plan”). The Rights Plan is designed to preserve ACETO’s net operating loss carryforwards (NOLs) and other significant tax benefits which may be available to reduce potential future tax liabilities.]]>https://www.globenewswire.com/news-release/2018/10/22/1624946/0/en/ACETO-Corporation-Schedules-First-Quarter-Fiscal-2019-Financial-Results-News-Release-and-Conference-Call.html?f=22&fvtc=4&fvtv=6436ACETO Corporation Schedules First Quarter & Fiscal 2019 Financial Results News Release and Conference Call2018-10-22T17:00:00Z<![CDATA[PORT WASHINGTON, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- ACETO Corporation (NASDAQ: ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, will issue its financial results of operations for the first quarter of fiscal 2019 ended September 30, 2018 after the stock market close on Thursday, November 8, 2018.]]>